New owner for Alcami

Global Healthcare Opportunities, a European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm, have agreed to acquire US-based CDMO Alcami from Madison Dearborn Partners and Ampersand Capital Partners. They will each have 50% stakes.

The deal, for which no terms were disclosed, is expected to close by the end of 2022, after customary closing conditions and regulatory approvals. Chairman and CEO Patrick Walsh called it “an ideal partnership in furthering Alcami’s strategic transformation, unprecedented growth rate and comprehensive service offerings”.

Since being created by the merger of Cambridge Major Laboratories and AAI Pharmaceutical Services, Alcami has grown through investments totalling $140 million, mainly in five sterile fill-finish manufacturing lines and additional laboratory space to support both biologic and small molecule programmes. It also acquired TriPharm Services and acquired Masy BioServices.

North Carolina-based Alcami is particularly known for drug product manufacturing focusing on sterile fill-finish of both biologics and small molecules; formulation development; lab services; and cGMP biostorage of high-value temperature-sensitive biologics, pharmaceuticals and materials.